Valmet Reports Mixed H1 2026: Sales Up, Orders Down Amid Market Uncertainty
Event summary
- Net sales rose 6% YoY to EUR 1.3B in Q2, while orders received dropped 10% to EUR 1.4B.
- Comparable EBITA increased 6% to EUR 152M, maintaining an 11.5% margin.
- H1 orders fell 14% YoY to EUR 2.5B, but net sales grew 6% to EUR 2.6B.
- Acquired Severn in July 2026, adding ~950 employees and expanding Process Performance Solutions segment.
The big picture
Valmet's H1 results reflect cautious industrial investment amid macroeconomic headwinds. The Severn acquisition bolsters its automation portfolio, but the company must navigate volatile biomaterial markets while maintaining operational efficiency gains. With net sales approaching EUR 5.2B annually, Valmet's ability to balance organic growth with strategic acquisitions will determine its long-term resilience.
What we're watching
- Market Recovery Timing
- Whether biomaterial capital project activity sustains sequential growth despite geopolitical uncertainty.
- Integration Success
- How effectively Valmet assimilates Severn's operations to drive Process Performance Solutions growth.
- Cost Discipline
- The pace at which SG&A cost reductions translate into sustained EBITA margin expansion.
Related topics